A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Activity of Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2019
Price : $35 *
At a glance
- Drugs Seladelpar (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors CymaBay Therapeutics
- 25 Nov 2019 Status changed from active, no longer recruiting to discontinued, based on initial histological findings observed in this study.
- 11 Jun 2019 Primary endpoint has not been met. (Relative change in MRI-PDFF at Week 12), according to a Cymabay Therapeutics media release.
- 11 Jun 2019 Results (12 weeks) presented in a CymaBay Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History